Posted in | News | Biofuels | Sustainability

Abraham Group Chosen by Dyadic International as Strategic Advisor

Biotechnology company Dyadic International, Inc. has selected consulting company The Abraham Group for providing transactional assistance and strategic advice to Dyadic International, even as it actively seeks licensing deals and other strategic partnerships throughout the globe.

Dyadic International’s C1 platform technology meets the requirements of the biofuels industry by producing industry-scale enzymes that transform biomass into ethanol as well as other alternative energy resources.

Using the C1 platform technology, cost-effective alternatives to petroleum-based products and oil can be produced. More than ten years of research and development efforts have gone into the C1 platform technology, which can be programmed to generate novel commercial-scale, cost-effective enzymes even under different operating conditions. These enzymes offer enhanced flexibility in processing different biomass types by biorefineries into sugars that are fermentable, which can be transformed into biofuels including butanol and ethanol in addition to polymers, plastics and chemicals.

Previously, Dyadic International has licensed the C1 platform technology to Abengoa Bioenergy, a biofuels and energy producer, in the biofuels area. The company also licensed the technology to Codexis. Dyadic International and these licenses continue to make improvements on the C1 platform technology in an effort to make production methods more efficient in generating low-cost biofuels at large quantities.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.